This phase I trial is evaluating a new intravenous drug treatment in patients with cancers that express a specific gene (NaPi2b), in particular patients with ovarian cancer or non-small cell lung cancer.
This trial is treating multiple types of cancer including cancers that express a specific gene (NaPi2b), such as ovarian cancer or non-small cell lung cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Eligible patients will receive XMT-1536 as an intravenous infusion once every four weeks. This is a dose escalation and expansion trial; patients in the dose escalation stage will receive increased doses of XMT-1536, until the patient(s) experience 2 or more dose-limiting events.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More